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ABSTRACT
This study evaluated a DNA oligonucleotide array that recognised 38 different Staphylococcus aureus
targets, including all relevant resistance determinants and some toxins and species-speciﬁc controls. A
new method for labelling sample DNA, based on a linear multiplex ampliﬁcation that incorporated
biotin-labelled dUTP into the amplicon, was established, and allowed detection of hybridisation of the
amplicons to the array with an enzymic precipitation reaction. The whole assay was validated by
hybridisations with a panel of reference strains and cloned speciﬁc PCR products of all targets. To
evaluate performance under routine conditions, the assay was used to test 100 methicillin-resistant
S. aureus (MRSA) isolates collected from a university hospital in Saxony, Germany. The results showed a
high correlation with conventional susceptibility data. The ermA and ermC macrolide resistance genes
were found in 40% and 32% of the isolates, respectively. The most prevalent aminoglycoside resistance
gene was aphA3 (57% of the isolates), followed by aacA–aphD (29%) and aadD (29%); tet genes, mupR
and dfrA were rare. There were no isolates with van genes or genes involved in resistance to
quinupristin–dalfopristin. Enterotoxins were detected in 27% of the isolates. Genes encoding Panton–
Valentine leukocidin, toxic shock syndrome toxin and exfoliative toxins were not found. The DNA array
facilitated rapid and reliable detection of resistance determinants and toxins under conditions used in a
routine laboratory and has the potential to be used for array-based high-throughput screening.
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INTRODUCTION
Susceptibility testing of microbial pathogens is
usually performed by measuring growth inhibi-
tion in the presence of deﬁned amounts of
antibiotics. However, such assays reveal only
phenotypes, without determining the underlying
molecular cause of resistance. The existence of
inducible phenotypes and different protocols for
testing, including varying compositions of growth
media as well as different national breakpoints,
complicate the interpretation of phenotypic sus-
ceptibility data. PCR-based methods that permit
the detection of speciﬁc resistance genes have
been introduced [1], but it is cumbersome to
screen high numbers of isolates, as it is often
necessary to perform several PCRs to detect one
resistance phenotype. DNA microarray techno-
logy allows the simultaneous detection of many
targets [2]. This approach could facilitate studies
of the epidemiology of resistance genes and the
prediction of resistance properties, even in slow-
growing or unculturable pathogens. DNA arrays
could also facilitate a genotype-based assessment
of the virulence of a given isolate by detecting
virulence-associated genes.
The aim of the present study was to develop an
array-based assay for use in a clinical laboratory
without substantial investments in hardware and
manpower. Staphylococcus aureus was selected as
the target organism because of the complexity of
its system of clinically important resistance deter-
minants and toxins. Multidrug resistance in
S. aureus causes major therapeutic problems
[3,4], with some strains being resistant to most
available antibiotics, including glycopeptides [5].
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Strains of S. aureus can also produce several
potent toxins [6,7], which cause food poisoning,
Ritter’s disease and toxic shock syndrome.
An oligonucleotide array covering the genes
encoding resistance determinants, toxins and
species-speciﬁc sequences of S. aureus was de-
signed. This was used to develop and optimise a
complete assay procedure, including DNA pre-
paration, ampliﬁcation and labelling, hybridisa-
tion and detection. The assay was ﬁrst validated
by performing hybridisations with positive and
negative control strains, as well as with cloned
speciﬁc PCR products for all targets covered.
Second, array-based genotypic data for clinical
isolates were compared with phenotypic results
from conventional susceptibility tests in order to
evaluate the clinical relevance of the genotypic
data. This kind of validation is necessary because
non-functional, truncated or non-expressed genes
might result in a false prediction of resistance,
and because sequence variations might cause a
false prediction of susceptibility.
MATERIALS AND METHODS
Isolates and culture
In total, 100 consecutive strains of methicillin-resistant S.
aureus (MRSA) isolated at the University Hospital, Dresden,
Germany in 2002–2003 were investigated. Duplicate isolates
from the same patient were excluded. Twenty isolates came
from intensive care units, three from the emergency depart-
ment, 34 from inpatients, 22 from outpatients, 20 from a long-
term rehabilitation centre, and one from a member of the
medical staff. The highest number of isolates (n = 34) was
obtained from diabetic foot ulcers. A further 24 isolates were
from MRSA screens (mostly nasal swabs) performed as part of
routine surveillance. Three isolates were from blood cultures
and one was from the cerebrospinal ﬂuid of a neurosurgical
patient. The remaining isolates were from surgical swabs,
respiratory specimens, stools or urine.
Specimens were spread on Columbia blood agar (Oxoid,
Wesel, Germany) and incubated overnight at 37C. Single
colonies were used for further subculturing. Screening for
clumping factor and coagulase was performed using Pastorex
Staph-Plus (Bio-Rad, Munich, Germany) and rabbit plasma
(Becton-Dickinson, Heidelberg, Germany). Routine suscepti-
bility tests were performed using the VITEK I system (bio-
Me´rieux, Nu¨rtingen, Germany) as recommended by the
manufacturer. Methicillin resistance was conﬁrmed by detec-
tion of penicillin-binding protein 2¢ (PBP2¢) using an agglutin-
ation assay (MRSA-screen; Innogenetics, Ghent, Belgium).
Penicillinase activity was detected using the BBL DrySlide
Nitroceﬁn test (Becton Dickinson).
MICs were determined by the standard agar dilution
technique with Mueller–Hinton broth (Oxoid) for erythromy-
cin, clindamycin, gentamicin, neomycin, tobramycin, amika-
cin, nurseothricin, ciproﬂoxacin, doxycycline, trimethoprim,
mupirocin and benzalconium chloride. Double-disk diffusion
tests were performed with erythromycin and clindamycin
(15 lg- and 2 lg-disks, respectively; Oxoid) as described
previously [8,9] if erythromycin-resistant isolates were found
to be susceptible to clindamycin. The presence of the entero-
toxin genes entA, entB and entC was determined by PCR as
described by Johnson et al. [10].
DNA preparation
Growth from a quarter of a standard plate of Columbia blood
agar yielded sufﬁcient bacterial cells after overnight incubation
at 37C. Harvested staphylococci were resuspended in 5 mL of
isotonic saline and centrifuged at 2300 g for 10 min. The pellet
was resuspended in 200 lL of lysis solution containing 0.1 mg
lysostaphin (Sigma, Steinheim, Germany), 4 mg lysozyme
(Sigma), 4 mg ribonuclease A (Sigma), 4 lL Tris-HCl (20 mM,
pH 8.0), 4 lL EDTA (2 mM), and 2 lL Triton X-100. Following
incubation on a shaker (45 min, 37C, 300 rpm), 25 lL of
proteinase K solution and 200 lL of buffer AL (both contained
in the DNeasy kit; Qiagen, Hilden, Germany) were added, and
this was followed by incubation for a further 45 min at 56C.
After the addition of 200 lL of ethanol, the extracted DNA was
puriﬁed on a spin column (DNeasy kit) according to the
manufacturer’s instructions. TheDNAconcentrationwas deter-
mined spectrophotometrically at 260 nm. As fragmentation of
DNA affects the overall sensitivity of the assay, gel electrophor-
esis and ethidium bromide staining were used to monitor
aliquots of the DNA preparations.
Probe design and DNA array preparation
Probe sequences were designed from published target se-
quences using the Array Design software package (Clondiag
Chip Technologies, Jena, Germany). Targets, Genebank acces-
sion numbers for sequence data and probe sequences are listed
in Table S1 (supplementary on-line material). Consensus
regions in the alignments of all available sequences of each
target were chosen for the probe design. Probe sequences were
selected to be speciﬁc for the target and to have similar lengths,
GC contents and melting temperatures in order to yield
comparable signal intensities. The ﬁnal probe sequences were
compared with all available sequences in the Genebank
database (http://www.ncbi.nlm.nih.gov/BLAST/) to exclude
any theoretical false-positive reactions caused by cross-reac-
tions, or false-negative reactions caused by sequence varia-
tions. Oligonucleotides (3¢-amino-modiﬁed) were synthesised
by Metabion (Martinsried, Germany), diluted in Spotting
Buffer 1 (Schott Nexterion, Jena, Germany) to a concentration
of 10 lM, and spotted on surface-coated glass (Clondiag) using
a Microgrid II spotting machine (Genomic Solutions, Hun-
tingdon, UK) according to the procedure supplied by the
manufacturer. Each probe was spotted ﬁve times on the array
(Fig. 1). After production, arrays were inserted into ArrayTube
reaction vials (Clondiag).
Primer design
The primer set for the linear ampliﬁcation procedure consisted
of 39 antisense oligonucleotides (one primer for every target,
but with two different primers for the 23S rRNA gene). A
consensus region was identiﬁed for each target, situated up to
100 bp upstream of the probe-binding site. Sequences with
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similar physicochemical parameters (see ‘Probe design’) were
chosen from these regions and used for primer design. Primer
sequences (Table S1) were compared with the Genebank
database to avoid theoretical cross-reactions or sequence
variations. Oligonucleotides were synthesised by Metabion,
and were used as a primer mixture containing each individual
primer at a concentration of 0.135 lmol/L.
Primer elongation reaction and labelling
The primer elongation reaction was performed using the
primer mixture and a dNTP solution containing 1 mM dATP,
1 mM dCTP, 1 mM dGTP, 0.65 mM dTTP and 0.35 mM biotin-
16-dUTP (Roche, Penzberg, Germany). Each elongation reac-
tion contained 0.3 lL Therminator polymerase (New England
Biolabs, Frankfurt, Germany), 3 lL Therminator polymerase
buffer (New England Biolabs), 3 lL primer solution, 3 lL
dNTP stock solution, and 1–1.5 lg unfragmented S. aureus
genomic DNA. Reaction conditions comprised 5 min at 96C,
followed by 45 cycles of 20 s at 62C, 40 s at 72C and 60 s at
96C. Each reaction was then cooled to 4C and used for
hybridisation with the DNA array.
Hybridisation and detection
Each ArrayTube was ﬁrst washed with 500 lL double-distilled
water and 500 lL Hybridisation Buffer I (Schott Nexterion,
Jena, Germany) using a thermomixing device (5 min at room
temperature, 550 rpm). A 20-lL aliquot of the labelled sample
was denatured in a separate microtube (2 min at 95C) and
then transferred into the ArrayTube and incubated for 60 min
at 50C (550 rpm). The sample was then removed from the
tube and the array was washed three times (5 min at room
temperature, 550 rpm), ﬁrst with 500 lL 2 · SSC
(1 · SSC = 0.15 M NaCl, 0.015 M trisodium citrate, pH 7.0)
containing Triton X-100 0.01% v ⁄v, then with 500 lL 2 · SSC,
and ﬁnally with 500 lL 0.2 · SSC. This was followed by the
addition of 100 lL of a 2% w ⁄v solution of blocking reagent
(Clondiag), dissolved in 6 · SSPE (1 · SSPE = 150 mM NaCl,
10 mM sodium phosphate, 1 mM EDTA) containing Triton
X-100 0.1% v ⁄v, and incubation of the ArrayTube for 15 min at
30C (550 rpm). Horseradish peroxidase–streptavidin conju-
gate (Clondiag) was diluted in 6 · SSPE containing Triton
X-100 0.1% v ⁄v to a concentration of 100 pg ⁄lL. The blocking
solution was removed and 100 lL of the diluted conjugate was
added to the ArrayTube; this was followed by incubation
(15 min, 30C, 550 rpm) and three washing steps as described
above. The ArrayTube was then placed into the ATR 01
reading device (Clondiag) and 100 lL TMB peroxidase sub-
strate (Clondiag) was added to start the staining reaction.
Measurements and data analysis
TheATR 01 reading device and IconoClust software (Clondiag)
were used according to the manufacturer’s instructions. After
staining for 10 min at 25C, an image of the array was recorded
and analysed. Signal intensity and local background were
measured for each probe position. Intensities of local back-
grounds were subtracted from the intensities of the automat-
ically recognised spots, and averages for all results of a given
probe were calculated. Resulting values of < 0.1 were consid-
ered negative, while those of > 0.3 were considered positive.
Values between 0.1 and 0.3 were considered to be equivocal
[11].
Validation
Validation was performed using two different approaches.
First, a positive and a negative control strain were deﬁned for
each target (Table S2) (supplementary on-line material) and
Fig. 1. Probe layout and microphotograph of a hybridised and stained array. The actual size of the array is 2.4 · 2.4 mm.
Spots designated ‘X’ are positioning biotin markers whose asymmetrical distribution allows the correct alignment of the
array to the grid.
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tested with the method described above. Second, PCRs were
developed for every target included in the present study in
order to verify the results from array-based experiments. The
primers for these PCRs (Table S2) were designed to include
both the probe-binding site and the primer-binding site of the
array-based assay. PCRs comprised 19.6 lL distilled water,
2.5 lL ·10 PCR buffer (containing 1.5 mM MgCl2), 0.5 lL
dNTPs (200 lM each dNTP), 0.5 lL each primer (10 lM),
0.4 lL Taq polymerase (5 U ⁄lL), and 1 lL sample DNA (all
reagents except for the sample DNA supplied by Promega,
Madison, WI, USA). PCR conditions were 2 min at 95C,
followed by 40 cycles of 30 s at 95C, 20 s at 55C and 2 min at
72C. A PCR product was obtained from the corresponding
positive control strain for every target represented on the
array, and was demonstrated to have the predicted amplicon
length by electrophoresis on 1% w ⁄v non-denaturing gels.
These PCR products were then used as templates instead of
staphylococcal genomic DNA, i.e., they were subjected to the
same labelling and hybridisation procedures as described
above. Additionally, all amplicons were cloned using the
TOPO TA cloning kit (Invitrogen, Karlsruhe, Germany)
according to the manufacturer’s instructions. Positive clones
were picked and subcultured, after which plasmids were
isolated using a Nucleo Spin Plasmid Kit (Macherei & Nagel,
Du¨ren, Germany) and digested with EcoRI (MBI Fermentas,
Vilnius, Lithuania). The length of the inserts was checked by
electrophoresis on 1% w ⁄v non-denaturing gels. Additionally
plasmids were partially sequenced. Plasmids with inserts were
labelled as described above and then used in hybridisation
experiments instead of genomic DNA, using an individual
array for each target.
RESULTS
Assay sensitivity
Adilution series of genomic DNA from oneMRSA
isolate was analysed, with 1, 0.5, 0.2, 0.1, 0.05 and
0.01 lg of unfragmented genomicDNAbeing used
in the labelling and subsequent hybridisation
reactions. The detection limit of the assay was
0.05 lg, equivalent to c. 1.7 · 107 DNA copies,
based on a genome size of 2.85 · 106 nucleotide
residues corresponding to a molecular mass of
1.76 · 109 g ⁄mol. However, in experiments with
dilution series, if the DNA content approached the
detection threshold, hybridisation signals of dif-
ferent probes sometimes had different intensities,
so that the detection limits for different target genes
might vary. This could result from steric effects
[12–14], either from parameters that inﬂuence the
stringency of binding (e.g., pH, ionic strength and
hybridisation temperature), or from sequence var-
iations within the binding regions of primers or
probes. To overcome these effects, relatively large
amounts of genomic DNA (1–1.5 lg) were used
routinely to ensure total saturation of the binding
capacity of each spot on the array.
Validation
All primer–probe combinations included in the
deﬁnitive array gave clearly positive signals with
the corresponding positive control strains, and
unambiguously negative signals with negative
control strains. These results were checked indi-
vidually for each target by PCR, using the primers
listed in Table S2. PCR products from positive
control strains and plasmids derived from these
PCR products were subjected to the entire ampli-
ﬁcation procedure with all 39 primers, followed
by array hybridisations. Each product hybridised
only with the corresponding probe on the array.
Genus- and species-speciﬁc markers
Reactions with 23S rRNA probes were always
positive. CoA, katA and femA gave either positive
or, in a few cases, ambiguous results (the katA
primer and probe were designed to be speciﬁc for
S. aureus, although coagulase-negative staphylo-
cocci also have a catalase gene). Results for norA
were positive for 59 isolates, negative for 21
isolates, and ambiguous for 20 isolates. The
results for norA showed no correlation with
ciproﬂoxacin MICs; of 98 ciproﬂoxacin-resistant
isolates (MIC > 4 mg ⁄L), 21 were norA-negative,
while both of the susceptible isolates
(MIC £ 1 mg ⁄L) were positive for norA.
Ten reference strains and isolates of coagulase-
negative staphylococci (S. epidermidis, S. hominis,
S. haemolyticus, S. warneri and S. lentus) were
tested as controls. All of these were negative for
S. aureus-speciﬁc markers, although they gave
positive signals with genus-speciﬁc 23S rRNA
probes, as well as with some other probes, such as
those for mecA or blaZ. In addition, DNA from
Escherichia coli, Yersinia enterocolitica, Enterococcus
faecium and Bacillus cereus was tested, but no
positive reaction with any of the genus- or
species-speciﬁc markers was observed.
The mecA and b-lactamase (blaZ) genes
All 100 MRSA isolates were positive for mecA in
array hybridisations, as well as for PBP2¢ in an
agglutination assay. Sixty-ﬁve blaZ-positive iso-
lates, and 13 isolates with equivocal results for
blaZ, had detectable penicillinase activity. Seven
isolates displayed neither hybridisation signals
for blaZ nor penicillinase activity. Thirteen
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isolates were positive (and one was equivocal) for
blaZ, but were negative in the nitrocephin assay.
One isolate showed clearly negative results in
repeated array hybridisations, although it had
detectable penicillinase activity.
Genes determining resistance to macrolides,
lincosamides and streptogramins
The most common macrolide resistance genes
were ermA (40 isolates) and ermC (32 isolates).
There were no isolates with multiple macrolide
resistance determinants. Seventy-one isolates
with erm genes had erythromycin MICs of
> 8 mg ⁄L; one isolate with ermC had an MIC of
4 mg ⁄L. The remaining 28 isolates were negative
for both ermA and ermC, and had erythromycin
MICs of £ 1 mg ⁄L. The msrA gene was not
detected.
The results for clindamycin were almost iden-
tical to those for erythromycin. Seventy-one erm-
positive isolates had MICs of > 8 mg ⁄L. One
ermC-positive isolate had a low clindamycin
MIC (£ 1 mg ⁄L), but the double-disk diffusion
test was positive, indicating an inducible resist-
ance. Twenty-eight erm-negative isolates had
MICs of £ 1 mg ⁄L. No isolate contained linA.
The streptogramin resistance determinants
vatA, vatB, vga, variant vgaA and vgb were not
detected, and none of the isolates was resistant to
quinupristin–dalfopristin.
Aminoglycoside resistance genes
No genes for aminoglycoside-modifying enzymes
were detected in 18 isolates, while 30 harboured
only aphA3, and 23 were positive only for aadD.
The remaining 29 isolates harboured combina-
tions of several genes for aminoglycoside-modify-
ing enzymes (aphA3 plus aacA–aphD in 23 isolates;
aadD plus aacA–aphD in two isolates; and all three
genes in four isolates). The 30 aphA3-positive
isolates had neomycin MICs of 32–128 mg ⁄L,
while the 23 aadD-positive isolates had MICs of
16–64 mg ⁄L. The 18 isolates with neither aphA3
nor aadD had MICs of 0.5–1 mg ⁄L. The remaining
29 isolates with combinations of several genes had
neomycin MICs ranging from 16 to 64 mg ⁄L.
Seventy-one isolates that did not harbour
aacA–aphD were susceptible to gentamicin (MICs
of 0.25–0.5 mg ⁄L), even if they harboured aphA3
or aadD, while 29 isolates that harboured
aacA–aphD in various combinations with other
genes were resistant to gentamicin (MIC ‡
8 mg ⁄L). Isolates with only aadD had tobramycin
MICs of ‡ 8 mg ⁄L, while isolates with gene
combinations including aadD and ⁄ or aacA–aphD
had MICs of 4 to ‡ 8 mg ⁄L. Isolates with either
aphA3 alone, or no genes for aminoglycoside-
modifying enzymes, had tobramycin MICs of
£ 1 mg ⁄L. All the isolates had amikacin MICs of
£ 4–8 mg ⁄L.
The sat gene and nurseothricin resistance
The sat gene was present in 57 isolates, which had
nurseothricin MICs of 8–64 mg ⁄L; MICs for neg-
ative isolates were £ 2 mg ⁄L. All sat-positive
isolates also harboured aphA3.
Glycopeptide resistance
The glycopeptide resistance determinants vanA,
vanB and vanZ were not detected, although
two isolates showed reduced susceptibility to
teicoplanin (MICs of 16 and 24 mg ⁄L, respect-
ively).
Resistance to tetracycline and trimethoprim
The tetK gene was detected in one isolate, and the
tetM gene in three isolates. All tet-positive isolates
had doxycycline MICs of ‡ 8 mg ⁄L, while all tet-
negative isolates had MICs of £ 1 mg ⁄L. The dfrA
gene was found in 12 isolates, including three
isolates with equivocal hybridisation results, all of
which had trimethoprim MICs of ‡ 64 mg ⁄L. Of
the dfrA-negative isolates, 75 had MICs of
1–4 mg ⁄L, nine had an MIC of 8 mg ⁄L, and four
had MICs of 16 to > 64 mg ⁄L.
Mupirocin and benzalconium chloride
resistance
Ninety-seven isolates were mupR-negative and
were susceptible to mupirocin (MIC 4 mg ⁄L).
Three isolates were mupR-positive and had MICs
of 256–1024 mg ⁄L. Four isolates with a benzalco-
nium chloride MIC of 8 mg ⁄L were qacA-positive.
Of 50 isolates with an MIC of 4 mg ⁄L, 11 were
qacA-positive and 39 were qacA-negative. Thirty-
ﬁve of 36 isolates with an MIC of 2 mg ⁄L, and all
ten isolates with an MIC of £ 1 mg ⁄L, were qacA-
negative.
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Staphylococcal toxins
The toxin-encoding genes tst1, etA, etB, lukF-PV
and lukS-PV were not detected. Twenty-seven
isolates harboured genes for enterotoxins. Sixteen
isolates were positive for entA, while two gave
ambiguous signals. The entB gene was detected in
two isolates, and two others were equivocal. The
entC gene was found in four isolates, and the entK
gene in two isolates. Positive hybridisation signals
for entQ were observed with two isolates, and
two others gave equivocal results. Two isolates
harboured multiple enterotoxins (entA + entB +
entK + entQ and entB + entK + entQ, respectively).
Fig. 2 summarises the overall prevalences of
the resistance and toxin genes investigated.
DISCUSSION
Several different DNA array-based assays are
currently in use [2], but most systems are very
expensive, time-consuming, technically demand-
ing and difﬁcult to adapt to the needs of high-
throughput screening. This restricts their use to
specialised research groups as opposed to diag-
nostic laboratories. In contrast, the assay
described in this article is relatively easy to
perform, and the use of tube-integrated arrays
with non-ﬂuorescent labelling and rapid hybrid-
isation protocols is time-saving, relatively inex-
pensive and allows large numbers of samples to
be analysed [11,15,16]. An isolate, once cultured,
can be processed within 1 day. The total cost per
assay is estimated to be c. 15 euro (plus 5 euro for
DNA preparation using the lysostaphin ⁄Qiagen
protocol described above). This is clearly less
expensive than comparable genotyping methods
(arrays or multiplex PCR), but is still greater
than the cost of a phenotypic susceptibility test
(c. 5 euro using an automated system such as the
VITEK). However, the above estimate is based on
small-scale experimental production rather than
commercial mass-production.
For the present assay, a set of synthetic oligo-
nucleotide primers was used to run a non-expo-
nential, but linear, ampliﬁcation. With the use of
only one primer per target in an ampliﬁcation
protocol otherwise identical to a standard PCR
protocol, a high rate of multiplexing with 39
possible reactions in one reaction mixture was
achieved. Another advantage of this design is the
high speciﬁcity, which resulted from two
Fig. 2. Prevalences of resistance determinants and genes encoding toxins among 100 isolates of methicillin-resistant
Staphylococcus aureus.
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consecutive site-speciﬁc hybridisations: ﬁrst,
between the primer and the target DNA; and
second, between the labelled amplicon and the
probe on the DNA array. A potential disadvan-
tage of the single primer design is reduced
sensitivity compared to a standard PCR, but this
is not important, as the assay was developed for
work with cultured bacteria rather than patient
samples. The necessary number of cells can be
obtained easily from an overnight plate culture, as
is the case when performing conventional sus-
ceptibility tests.
Following validation of the array by hybridisa-
tions with control strains and PCR products ⁄plas-
mids derived from these strains, as well as by
bioinformatics analysis, the array-based data were
evaluated by comparison with conventional sus-
ceptibility tests for a panel of clinical isolates. For
23S rRNA sequences, coA, femA, katA, mecA,
macrolide and aminoglycoside resistance deter-
minants, tet genes, sat and mupR, the correlation
approached 100%, similar to that reported previ-
ously for multiplex PCR systems with S. aureus
patient isolates [1].
Notable discrepancies between the genotypic
and phenotypic results were observed only for
norA, blaZ, dfrA and qacA. A high proportion of
isolates showed no norA signal, or equivocal
signals, even for samples with high DNA concen-
trations. This could indicate that some isolates
lack norA, or that there were sequence polymor-
phisms, although the published sequences were
accounted for by the present assay. A previous
study [17] has mentioned divergent sequences in
norA, which may render norA unsuitable as a
species-speciﬁc marker for S. aureus. The absence
of any correlation between the norA results and
MICs of ciproﬂoxacin conﬁrms that ﬂuoroquino-
lone resistance is not related simply to the
presence of norA [18].
Some isolates gave hybridisation signals for
blaZ, although no b-lactamase activity was detec-
ted. However, the b-lactamase gene might not be
expressed (or could even be lost) in MRSA
isolates without disadvantage. One isolate was
negative for blaZ, but had b-lactamase activity.
This result may be caused by sequence variations.
Similarly, the MICs for three dfrA-negative iso-
lates were as high as the MICs for positive
isolates, indicating either the presence of an
alternative trimethoprim resistance mechanism
or signiﬁcant sequence variation within the
binding regions of the dfrA primer and ⁄ or probe.
Benzalconium chloride was not a distinctive
marker for qacA, and a previous study [19] also
found only small differences in MICs between
qacA-positive and qacA-negative isolates.
There was a high correlation between the
array-based data for aminoglycoside-modifying
enzymes and the substrate speciﬁcity of the
corresponding enzymes [20]. The aphA3 gene
caused resistance to neomycin, but not to
gentamicin or tobramycin. The aacA–aphD gene
clearly conferred resistance to gentamicin, but all
aacA–aphD-positive isolates also contained other
aminoglycoside resistance genes. However, the
MICs suggested that aacA–aphD had an inﬂuence
on tobramycin, but not on neomycin resistance.
The aadD gene determined resistance to tobramy-
cin and neomycin, but did not affect gentamicin
susceptibility. No isolates were resistant to ami-
kacin, but as amikacin resistance has been repor-
ted in aadD- or aacA–aphD-positive strains [21], it
would be interesting to investigate the expression
of these genes.
Aminoglycoside resistance genes were found to
be common, but their prevalences differed signi-
ﬁcantly from those found in a European survey of
191 MRSA isolates [22], which reported preval-
ence rates of 76% for aacA–aphD, 53% for ant4¢
(synonymous with aadD), and 7% for aphA3, with
many isolates harbouring several aminoglycoside
resistance genes. The sat gene appeared to be
linked to aphA3, as also reported by Moon et al.
[23], and Derbise et al. [24] sequenced a transpo-
son, Tn5405, containing both genes (plus another
aad aminoglycoside resistance determinant). This
combination has also been observed in S. inter-
medius [25] and enterococci [26]. It was surprising
to ﬁnd sat in a majority of isolates, but this may be
related to the historical use of streptomycin
preparations contaminated with streptothricin
(W. Witte, personal communication), or to the
use of streptothricin in East German agriculture
before 1989 [26,27].
The prevalences of the ermA and ermC erythro-
mycin resistance genes were virtually identical to
those found in another German survey [28], in
which the rarity of msrA was also observed. The
linA gene was not detected, and all observed cases
of clindamycin resistance were attributable to
erm genes. One erm-positive isolate showed
inducible clindamycin resistance, which can cause
treatment failure [29]. No resistance to quinu-
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pristin–dalfopristin was found, and none of the
responsible genes were detected. Quinupristin–
dalfopristin had been used only occasionally in
the hospital from which the isolates were collec-
ted, and none of the patients from whom these
isolates were obtained had received this drug.
The tetK and tetM genes were detected rarely,
but there was complete correlation between
susceptibility tests and hybridisation results.
None of the isolates harboured both genes,
which is in contrast to a recent study [30] that
found both genes in nearly one-third (21 of 66) of
tetracycline-resistant strains sampled across
Europe; however, there was only a small number
of tetracycline-resistant isolates in the present
study.
The toxin-encoding tst1, etA and etB genes were
not found in the MRSA isolates tested in the
present study, and none of the patients had a
clinical condition which might have been related
to these toxins. However, several isolates con-
tained genes for enterotoxins, and two isolates
had multiple enterotoxin genes corresponding
to a pathogenicity island (entB + entK + entQ)
described by Yarwood et al. [31]. The genes for
Panton–Valentine leukocidin (lukF-PV and lukS-
PV) were not detected in any of the isolates
investigated, but an emerging epidemic strain
of community-acquired MRSA containing the
Panton–Valentine leukocidin genes [32,33] was
detected with the array after the end of the study
period (unpublished results).
The results of the present study demonstrate
that the DNA array technology is a useful tool for
the rapid detection of staphylococcal toxins and
studies of the epidemiology of antimicrobial
resistance genes. The proposed array can be
expanded easily with additional target genes
and can also be adapted for experiments with
other pathogens. The proposed technical platform
was suitable for use under routine conditions in a
reference laboratory or in the laboratory of a
tertiary-care facility.
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